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Abstract
Background: Preoperative neoadjuvant therapy for colorectal liver metastases (CRLM) is increasing in use and can
lead to chemotherapy-induced damage to sinusoidal integrity, namely sinusoidal obstruction syndrome (SOS). SOS
has been associated with an increased need for intraoperative blood transfusions, increased length of hospitalization
post-surgery, decreased tumor response, and a shorter overall survival after resection due to liver insufficiency. It is
critical for clinicians and pathologists to be aware of this type of liver injury, and for pathologists to include the status
of the background, non-neoplastic liver parenchyma in their pathology reports. In this study, expression of CD34 by
sinusoidal endothelial cells (SECs), increased expression of smooth muscle actin (SMA) by hepatic stellate cells (HSCs),
and aberrant expression of glutamine synthetase (GS) by noncentrizonal hepatocytes were semiquantitatively
evaluated in liver resection or biopsy specimens from patients with CRLM to determine their diagnostic value for
assessing chemotherapy-induced sinusoidal injury (CSI).
Methods: The expression of each marker was compared among 22 patients with CRLM with histologically evident
SOS (SOS+) and 8 patients with CRLM who had not undergone chemotherapy. Each case was given a histologic grade
using the sinusoidal obstruction syndrome index score (SOS-I) to assess the likelihood of SOS. Cases were also given an
immunohistochemical grade using the total CSI score calculated as the sum of CD34, SMA, and GS scores.
Results: Abnormal staining patterns for CD34 and SMA were significantly more frequent and extensive in SOS+ cases
than in the controls (81.8% vs. 25%, P < 0.01; 72.7% vs. 25%, P = 0.03). Aberrant GS expression in midzonal and periportal
hepatocytes was only observed in SOS+ cases (31.8% vs. 0%), but this difference did not reach statistical significance.
The CSI score was significantly higher in the SOS+ cases when compared to controls (P < 0.01), and was associated
with a higher SOS histologic grade (P = 0.02).
Conclusions: The CSI score, calculated using an immunohistochemical panel consisting of CD34, SMA, and GS, may
serve as an objective marker of chemotherapy-induced sinusoidal injury and could help diagnose this peculiar form of
liver injury.
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Background
The liver is the most frequent site of colorectal cancer
metastases. Approximately 15 to 25% of patients present
with synchronous, and 25 to 30% develop metachronous
liver metastasis [1]. Curative metastasectomy is possible
in the setting of liver-limited metastases; however, only
15 to 20% of patients are considered candidates for hepatic
resection at the time of presentation. Systemic chemo-
therapy in the preoperative setting is increasingly used
to improve the potential benefit of surgery and to down-
stage initially unresectable disease, allowing for potentially
curative surgery [2, 3]. The latter strategy, referred to as
“conversion chemotherapy” or “downsizing therapy,” is a
major reason for the yearly increase in the number of liver
resections for colorectal liver metastases (CRLM). The
most commonly used CRLM chemotherapy regimens
include oxaliplatin (OX) plus 5-fluorouracil (5-FU) and
leucovorin (FOLFOX) and irinotecan plus 5-FU and
leucovorin (FOLFIRI). As chemotherapy is often ad-
ministered prior to hepatic resection, adverse effects
on the background liver parenchyma of CRLM patients
are increasingly recognized [4, 5]. Recent meta-analysis
studies have demonstrated that the nature of preoperative
chemotherapy liver injury is a regimen-specific phenomenon
[6]. For example, OX-based regimens are associated
with sinusoidal injury, whereas irinotecan-based regimens
are associated with steatohepatitis. In the context of liver
surgery, chemotherapy-induced liver injury could increase
the risks of intra- and postoperative complications and
postoperative liver insufficiency [7].
Sinusoidal obstruction syndrome (SOS), previously
termed veno-occlusive disease (VOD), is considered the re-
sult of severe toxic injury affecting hepatic sinusoidal endo-
thelial cells (SECs). SOS has been associated with the use of
OX-based systemic chemotherapy, cytoreductive therapy
prior to hematopoietic stem cell transplantation, hep-
atic irradiation, pyrrolizidine alkaloid-containing herbal
remedies, liver transplantation, and a rare autosomal
recessive disorder of the liver and immune system (hepatic
veno-occlusive disease with immunodeficiency) [8]. Macro-
scopically, the affected liver typically has a characteristic
bluish-red marbled appearance and therefore, has been
called “blue liver syndrome”. Histologically, SOS is charac-
terized by distinct areas of dilated sinusoids with conges-
tion, which may be associated with liver cell plate atrophy.
In severe cases, it can also be associated with perisinusoidal
fibrosis, nodular regenerative hyperplasia (NRH), ob-
struction of centrilobular veins, and peliotic change [9].
The reported incidence of OX-induced SOS varies between
8.3 and 54% [9, 10]. Patients with OX-induced SOS in the
setting of CRLM have significantly impaired functional
hepatic reserve and are predisposed to increased blood
transfusions and higher morbidity after the hepatic re-
section [7]. Recent studies have demonstrated that SOS
induced by OX-based chemotherapy might diminish
the response to chemotherapy in patients with CRLM
[11, 12]. SOS may also compromise liver regeneration
in patients undergoing hepatectomy [13]. Therefore,
both pathologists and clinicians should be aware of this
syndrome as it has a relatively high prevalence and may
affect patient outcomes.
“Sinusoidal capillarization” is the altered phenotype
of SECs characterized by increased CD34 expression,
basement membrane formation, and decreased fenestrae
numbers, and is typically seen at the periphery of cirrhotic
nodules. In cases of OX-induced liver injury, increased
CD34 expression by SECs has been associated with the
severity of sinusoidal injury and deterioration of hepatic
functional reserve [14, 15]. It is well known that hepatic
stellate cells (HSCs) transform from a quiescent vitamin
A-rich type to a myofibroblastic fibrogenic phenotype
that can produce excessive amounts of extracellular matrix,
leading to perisinusoidal fibrosis [16]. While centrilobular
perisinusoidal/venular fibrosis is often reported in cases
with OX-induced liver injury, the expression status of SMA
by HSCs has only been sporadically described in this
clinical setting [17, 18]. In the normal liver, GS is expressed
exclusively in a narrow rim of pericentral hepatocytes; how-
ever, the area of GS-expressing hepatocytes has recently
been shown to be significantly expanded in several patho-
logic conditions including focal nodular hyperplasia (FNH),
liver cirrhosis of various etiologies, and idiopathic portal
hypertension [19–22]. Because these conditions are associ-
ated with altered intrahepatic blood flow caused by shunt
vessels or the presence of aberrant vasculature, impaired
sinusoidal microcirculation in SOS may also lead to altered
GS expression in the hepatic lobules.
The primary objective of this study was to assess the
value of immunohistochemical labeling for CD34, SMA,
and GS in the diagnosis of SOS after chemotherapy for
CRLM and to develop a scoring system that could be
easily implemented by pathologists. Each case was given a
histologic grade using the sinusoidal obstruction syndrome
index score (SOS-I) to assess the likelihood of SOS. Cases
were also given an immunohistochemical grade using the
total chemotherapy-induced sinusoidal injury (CSI) score
calculated as the sum of CD34, SMA, and GS scores. The
relationship between the CSI score and histologic disease
severity was also assessed.
Methods
Patient and tissue selection
Following institutional review board approval, this
study was conducted in the Department of Pathology at
the University of Pittsburgh Medical Center (UPMC),
Presbyterian Hospital. Between January 2012 and December
2013, 121 patients (74 males and 47 females, aged 28 to
91 years, median: 60 years) underwent liver resection
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for either synchronous or metachronous CRLM or liver
biopsy to evaluate the background liver parenchyma. Before
the procedure, 72 patients were treated with OX-based
chemotherapy, 16 patients were initially treated with OX-
based chemotherapy and later converted to irinotecan-
based chemotherapy, 9 were treated with irinotecan-based
chemotherapy, and 13 were treated with either 5-FU or oral
capecitabine alone. Eleven subjects received no chemother-
apy. Among these patients, routine histology slides were
available in 107 cases. For these cases, hematoxylin & eosin
(H&E)-stained non-neoplastic liver parenchyma slides were
blindly and independently evaluated by two hepatopatholo-
gists (H.L.S. and E.S.). Three exclusion criteria were applied
to minimize confounding effects of other possible signifi-
cant liver injuries and secondary changes resulting from
surgery and/or a possible tumor mass effect. These in-
cluded: 1) the presence of moderate to severe steatosis
(steatosis involving greater than 33% of hepatocytes) 2)
cases in which the only non-neoplastic liver paren-
chyma was within 1.5 cm of the cauterized margin or
tumor nodules, and 3) cases with well-developed bridg-
ing fibrosis or nodule formation. As a result, 40 cases
with available slides not meeting the above criteria were
excluded from the remainder of the study. For the
remaining 67 cases, the likelihood of SOS was assessed
based on: 1) the degree of sinusoidal injury, 2) the pres-
ence or absence of NRH, and 3) the presence or absence
of partial or total venous obstruction as shown in Table 1.
The SOS-I was then calculated by summing the sinusoidal
injury, NRH, and venous occlusion scores in each case
similar to that described previously by Rubbia-Brandt et
al. [9]. For those with an SOS-I ≥2 and 0/1, the cases were
classified as SOS+ and SOS–, respectively. Of the 67
cases evaluated, all 11 control cases were SOS–. Among
the cases treated with chemotherapy, 31 (55.4%) cases
were SOS– and 25 (44.6%) cases were SOS+. Of these
cases, tissue blocks were available for 8 controls and 22
SOS+ cases. Masson’s trichrome and immunohistochemi-
cal stains for CD34, SMA, and GS were performed in
these cases. The trichrome stain was blindly evaluated by
two hepatopathologists (H.L.S. and E.S.) and scored as 0
or 1, as shown Table 2.
Immunohistochemistry
Routinely formalin-fixed and paraffin-embedded liver
samples were immunostained with indirect immunohisto-
chemistry using monoclonal antibodies to CD34, SMA,
and GS, followed by the appropriate secondary antibodies.
The details of the primary antibodies used, their dilutions,
and the procedure for antigen retrieval are summarized in
Table 3. The reactions were revealed with 3-amino-9-ethyl-
carbazol (ScyTek Laboratories, West Logan, UT, USA) as a
chromogen and then lightly counterstained with modified
Gill’s hematoxylin (Ventana Medical Systems, Tucson, AZ,
USA). The immunohistochemical stains for CD34, SMA,
and GS were blindly evaluated by one of the authors (E.S.)
in a semiquantitative manner as shown in Table 4. Briefly,
each stain was evaluated and given a staining intensity
score of 0 to 3; the results of which were summed to
give the CSI score.
Statistics
Comparisons between the two groups were carried out
with Mann–Whitney U test or Fisher’s exact test using
StatPlus:mac Pro (Version 6.1, AnalystSoft Inc., Walnut,
CA). Differences were considered significant at P < 0.05.
Results
Histological evaluation
The histologic grade and chemotherapy details in each
of these 30 cases are summarized in Table 5. The histo-
logic findings of representative cases are shown in Fig. 1a
(control) and Fig. 2a-d (SOS+ cases). Of the 22 SOS+
cases, 17 were treated with OX-based chemotherapy, 4
were initially treated with OX-based chemotherapy
and later converted to irinotecan-based chemotherapy,
and 1 was principally treated with irinotecan-based
chemotherapy. The number of treatment cycles with
OX-based chemotherapy was available in 15 cases, and
the average was 5.5. In our series, unequivocal venous
occlusion was found in only one SOS+ case treated
with a FOLFOX regimen (4.5%) (Table 5, Case 14; see
also Fig. 2d), and most cases were categorized as SOS+
based on a combination of sinusoidal injury and NRH
Table 1 Histologic grading of sinusoidal obstruction syndrome
Sinusoidal Injury (SI)
0 - No sinusoidal dilatation or congestion
1 - patchy/confluent areas of sinusoidal dilatation/congestion without
hepatocyte atrophy
2 - patchy/confluent areas of sinusoidal dilatation/congestion with
associated mild hepatocyte atrophy
3 - patchy/confluent areas of sinusoidal dilatation/congestion with
associated moderate or severe hepatocyte atrophy





1 - present, partial obstruction of central venule(s)
2 - present, total occlusion of central venule(s)
Adapted from Rubbia-Brandt et al. [9]
Table 2 Grading of trichrome stain
0 - no perisinusoidal fibrosis
1 - perisinusoidal fibrosis in the areas of sinusoidal dilatation/hepatocyte
atrophy
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scores (63.6%) or sinusoidal injury score alone (31.8%).
The SOS-I score of the control cases was less than 2 in
all cases, and the majority had an SOS-I of score 1
(75%, 6/8), mostly due to sinusoidal dilatation and conges-
tion without significant hepatocyte atrophy. The trichrome
stain highlighted perisinusoidal fibrosis in 59% (13/22) of
SOS+ cases and 37.5% (3/8) of control cases. There was
no statistical difference in the trichrome staining results
between the SOS+ and control groups (P = 0.42).
Staining profile for CD34, SMA, and GS
The immunohistochemical results for CD34, SMA, and
GS are summarized in Table 5. The normal staining
patterns of CD34, SMA, and GS in a control case are
shown in Fig. 1, and the abnormal staining patterns of
CD34, SMA, and GS observed in representative SOS+
cases are shown in Fig. 3. Aberrant CD34 expression
in sinusoidal lining cells was significantly more fre-
quent in SOS+ cases (81.8%, 18/22) than in controls
25% (2/8) (P < 0.01), and the CD34 score of SOS+
cases was also significantly higher than that of the
controls (P < 0.01). As reflected in the scoring system
(see Table 4), the areas of aberrant CD34 expression in
SECs first appear in the periportal area and then
coalesce into periportal to periportal bridging and fur-
ther extend to the midzonal and centrizonal areas
(Fig. 3a). The areas of aberrant CD34 expression, when
present, were observed in multiple areas within the
examined samples and were not limited to the areas
with histologically recognizable sinusoidal dilatation/
congestion. Conversely, SMA expression in perisinusoidal
HSCs was more frequently observed in the centrizonal
and midzonal areas than in periportal areas. SMA-positive
HSCs varied in size and shape but often showed stretched,
long cytoplasmic processes that resulted in a confluent
linear staining pattern along the perisinusoidal space of
Disse (Fig. 3b). The areas showing SMA overexpression in
HSCs were multifocal and not limited to the areas with
histologically evident sinusoidal dilatation/congestion.
SMA expression in HSCs was significantly more frequent
in the SOS+ group (72.7%, 16/22) than in the control
group (25%, 2/8) (P = 0.03), and the SOS+ group SMA
score was higher (P = 0.02). Aberrant GS expression in the
midzonal and periportal hepatocytes was less frequent
compared to CD34 and SMA. All GS-positive cases were
SOS+ (31.8%, 7 of 22) (Fig. 3c and d), and none of the
control cases showed aberrant GS expression in either
midzonal or periportal hepatocytes (0%, 0 of 8), but this
difference did not reach statistical significance (P = 0.14).
Notably, 6/7 GS-positive cases showed relatively high
SOS-I (SOS-I of 3 or 4) including one case with VOD.
Chemotherapy-induced sinusoidal injury (CSI) score
The CSI score was calculated as the sum of the CD34,
SMA, and GS scores. The CSI score of the SOS+ group
(mean ± standard deviation, 4.82 ± 2.60) was signifi-
cantly higher than that of the control group (1 ± 1.20)
(P < 0.01, Fig. 4a). Within the SOS+ group, the cases
with the highest SOS-I (SOS-I = 4) showed significantly
higher CSI scores (6.71 ± 1.38) than cases with lower
SOS-I (SOS-I = 2 or 3) (3.93 ± 2.56) (P = 0.02, Fig. 4b).
Discussion
Chemotherapy for CRLM has dramatically improved
over the past 15 years, with tumor response rates in-
creasing from 20% with 5-FU alone to 60 to 70% using
variable combinations of new chemotherapeutic agents
[3]. The current mainstay of chemotherapy for CRLM is
FOLFIRI or FOLFOX and the standard chemotherapy
Table 3 Antibodies used in the study and their specifications
Antibody Cat number/clone Source Dilution Antigen retrieval
CD34 M7165/clone QBEnd-10 DAKO (Carpinteria, CA, USA) 1:25 Steam slides in preheated Target Retrieval Solution,
pH 9 (Carpinteria, CA, USA) for 30 min
SMA M0851/clone 1A4 DAKO (Carpinteria, CA, USA) 1:50 None
GS MAB302/clone GS-6 EMD Millipore (Billerica, MA, USA) 1:2000 Steam slides in pre-heated Target Retrieval Solution,
Citrate pH 6 (Carpinteria, CA, USA) for 60 min
Table 4 Grading of CD34, smooth muscle actin and glutamine
synthetase staining
CD34
0 - no periportal sinusoidal staining or focal, (non-circumferential)
periportal sinusoidal staining
1 - circumferential periportal sinusoidal staining present
2 - bridging (zone 1 to zone 1) sinusoidal staining present
3 - 2 and midzonal to centrizonal (zone 2 to zone 3) staining
Smooth Muscle Actin
0 - no apparent staining or rare isolated positive cells in the
perisinusoidal space
1 - many positive cells without linear/continuous pattern of
perisinusoidal staining
2 - focal linear/continuous pattern of perisinusoidal staining
3 - multifocal linear/continuous perisinusoidal staining
Glutasmine Synthetase
0 - normal perivenular staining pattern
1 - focal midzonal (zone 2) staining present
2 - multifocal midzonal (zone 2) staining present
3 - unequivocal confluent midzonal to periportal staining, if any
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backbone in first-line treatment has gradually been shifting
from FOLFIRI to FOLFOX during the last decade [23, 24].
While the use of modern chemotherapy regimens has dra-
matically improved the CRLM response rate, its toxicity on
the background liver parenchyma is becoming more recog-
nized. OX-based regimens are associated with SEC injury,
which may manifest as SOS, centrilobular, perisinusoidal,
or venular fibrosis, NRH, and peliosis-like changes in severe
cases [6, 25]. SOS has been associated with an increased
need for intraoperative blood transfusions, an increase
in the length of stay in the hospital after surgery [7], a
decrease in response to chemotherapy [11, 12], early
recurrence after resection and a short overall survival
after resection due to liver insufficiency [26, 27].
SOS was originally termed hepatic VOD; however,
recent experimental studies in pyrrolizidine alkaloid
(monocrotaline)-treated rats have clarified that the
main injury occurs at the level of the hepatic sinusoids, in-
dicating that central vein involvement is not essential for
SOS development [28]. SOS is caused by toxic injury to
SECs and loss of sinusoidal wall integrity with subsequent
sinusoid blockage by embolized sinusoidal lining cells.
Impaired sinusoidal microcirculation leads to metabolic
dysfunction and ischemic damage of adjacent liver cell
Table 5 Expression of CD34, smooth muscle actin and glutamine synthetase in patients with chemotherapy-induced SOS
Case Histologic Grade Trichrome Immunohistochemistry
Grade
No. Agea SI NRH VO SOS-I CD34 SMA GS CSI score Chemotherapy (cycle #)
1 70–74 3 1 0 4 1 3 3 0 6 capecitabine and oxaliplatin (2)
2 65–69 3 1 0 4 1 3 3 0 6 FOLFOX (4)
3 65–69 3 1 0 4 0 3 3 0 6 capecitabin, oxaliplatin (2) and cetuximab
4 55–59 3 1 0 4 0 3 1 3 7 FOLFOX (*) and bevacizumab
5 65–69 3 1 0 4 1 3 2 3 8 FOLFOX (*)
6 60–64 3 1 0 4 1 3 3 3 9 FOLFOX (6)
7 70–74 3 1 0 4 0 2 3 0 5 FOLFOX and bevacizumab (6)
8 50–54 2 1 0 3 1 0 0 0 0 FOLFOX (6)
9 70–74 2 1 0 3 1 2 0 0 2 FOLFOX (*)
10 65–69 2 1 0 3 0 2 3 0 5 FOLFOX (*) and bevacizumab
11 65–69 3 0 0 3 1 3 3 2 8 FOLFOX (4)
12 55–59 3 0 0 3 1 3 3 1 7 FOLFOX (3) and bevacizumab
13 75–79 2 1 0 3 0 3 0 0 3 FOLFOX (*)
14 70–74 0 1 2 3 1 0 3 3 6 FOLFOX (12)
15 30–34 1 1 0 2 0 2 3 0 5 FOLFOX (8), converted to FOLFIRI and bevacizumab
16 50–54 2 0 0 2 1 2 3 0 5 FOLFOX (6) and cetuximab
17 50–54 2 0 0 2 0 0 0 0 0 FOLFOX (8), converted to FOLFIRI, bevacizumab and cetuximab
18 55–59 2 0 0 2 0 0 3 0 3 FOLFOX (4) and bevacizumab
19 45–49 2 0 0 2 1 1 3 3 7 FOLFOX (5) and cetuximab converted to FOLFIRI
20 55–59 1 1 0 2 0 1 0 0 1 FOLFOX (6)
21 55–59 2 0 0 2 1 2 3 0 5 FOLFOX (*), converted to FOLFIRI, avastin and cetuximab
22 50–54 1 1 0 2 1 2 0 0 2 FOLFIRI and cetuximab
23 55–59 1 0 0 1 1 0 2 0 2 none
24 60–64 1 0 0 1 0 1 0 0 1 none
25 50–54 0 1 0 1 1 2 0 0 2 none
26 70–74 1 0 0 1 0 0 0 0 0 none
27 60–64 1 0 0 1 1 0 3 0 3 none
28 55–59 1 0 0 1 0 0 0 0 0 none
29 85–89 0 0 0 0 0 0 0 0 0 none
30 75–79 0 0 0 0 0 0 0 0 0 none
aAges were replaced by age ranges to maintain partient confidentiality
SOS sinusoidal obstruction syndrome, SI sinusoidal injury, NRH nodular regenerative hyperplasia, VO venous obstruction, SOS-I SOS index, SMA smooth muscle
actin, GS glutamine synthetase, CSI score chemotherapy-induced sinusoidal injury score, OX oxaliplatin, *unknown cycle
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plates, which may cause atrophy and/or dissociation of
liver cell plates and further focal hepatocellular necro-
sis/dropout.
The histopathologic spectrum of OX-associated liver
lesions was extensively investigated by Rubbia-Brandt et al.
in a large series of surgically resected CRLM [9]. According
to their study, 54% of patients treated with OX-based regi-
mens had moderate/severe SOS, 47% showed centrilobular
perisinusoidal/venular fibrosis, 24.5% developed NRH, and
10.6% manifested peliosis hepatis, while the 111 patients
treated by surgery alone had no such lesions. Although the
histologic spectrum of OX-associated liver lesions has been
well documented, the precise histopathologic diagnosis of
OX-associated liver injury in the setting of CRLM can be
potentially difficult, due to several reasons. First, surgically
resected liver specimens for CRLM contain tumor nodules
of varying sizes; therefore, the histologic changes of OX-
associated liver injury might be obscured by or misinter-
preted as local mechanical and/or hemodynamic changes
caused by tumor mass effect. This is why it is critical to
sample the non-neoplastic liver away from the tumor/tu-
mors; ideally we suggest greater than 1.5 cm away from the
metastatic lesions. Second, SOS lesions can be patchy and
more prominent in the subcapsular region. Uneven lesion
distribution may make diagnosis difficult, particularly in
biopsy samples. Even in resection specimens, it may be
difficult to differentiate whether focally enhanced sinusoidal
dilatation/congestion is clinically an irrelevant localized
change or a true manifestation of SOS. Our stains appeared
to detect SOS lesions diffusely throughout the liver paren-
chyma and may reduce this potential sampling error. Third,
the histologic detection of perisinusoidal fibrosis and NRH
changes might potentially be difficult to detect by inexperi-
enced pathologists, especially without the use of special
stains such as trichrome and reticulin, which are not rou-
tinely performed on CRLM specimens. While awareness of
the histologic spectrum of OX-induced liver injury, careful
examination of precise areas, and appropriate use of special
stains would reduce diagnostic errors, additional markers of
sinusoidal endothelial injury would further improve the
diagnosis and provide a more objective assessment of this
unusual type of liver injury.
Hepatic SECs are highly specialized endothelial cells
characterized by fenestrations and the absence of an orga-
nized basement membrane. Fenestrae are grouped into
sieve plates and control the exchange of fluids, solutes,
and particles between the sinusoidal blood and the space
of Disse, which contains numerous protruding microvilli
of hepatocytes. Unlike vascular endothelium elsewhere in
the body (except for splenic sinusoids), hepatic SECs do
not express CD34 other than the small areas directly
adjacent to portal tracts [29]. In normal conditions,
Fig. 1 An example of a control group (case 29 in Table 5) in which a patient with CLRM did not receive chemotherapy prior to resection. a This
case showed no significant sinusoidal dilatation, congestion, or parenchymal nodularity (H&E, ×40). b An immunohistochemical stain for CD34
showed the normal staining pattern with only focal weak sinusoidal staining around the portal tracts (arrows, ×200). c Positive immunoreactivity
for smooth muscle actin (SMA) was seen in the portal blood vessels, bile ducts, and central venules. No SMA-positive stellate cells were present in
the lobules (×200). d An immunohistochemical stain for GS revealed a normal perivenular staining pattern (×100)
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hepatocytes and HSCs maintain the normal SEC pheno-
type; however, in chronic liver disease, the SECs undergo a
phenotypic shift to regular vascular endothelium that is
termed “sinusoidal capillarization” [30]. In such conditions,
capillarized SECs lack fenestration, develop an organized
basement membrane, and express CD34. Sinusoidal capil-
larization by means of immunohistochemistry for CD34
was observed in 81.8% of SOS+ cases, which was statisti-
cally more frequent and more extensive than in controls.
To date, immunohistochemical CD34 assessment of
sinusoidal capillarization in the setting of chemotherapy-
induced liver injury in patients with CRLM has only been
reported in a few studies. According to Narita et al., SOS
was found in 39 of 80 patients treated with hepatic resec-
tion for CRLM after chemotherapy, of which 33 (85%)
showed sinusoidal CD34 overexpression [14]. They also
found that age over 70 years, male sex, and the presence
of SOS were independent factors associated with CD34
overexpression. Nalbantoglu et al. demonstrated aberrant
capillarization of the sinusoids by CD34 labeling in 98%
(45/46) of cases treated with hepatic resection for CRLM
after OX-based chemotherapy, and 41% (19/46) showed
extensive staining throughout the lobule [15]. In their
series, the overall frequency of sinusoidal capillarization
by CD34 was much more frequent than that of histologi-
cally recognized OX-induced liver injury (68.1%, 32/47),
and extensive multifocal CD34 expression was associ-
ated with liver injury severity. As evidenced by our
study and others, sinusoidal capillarization is quite fre-
quent in patients with CSI and CRLM and appears to
be a fairly early event in the SOS disease process.
While SMA upregulation in activated HSCs has been
sporadically reported in VOD of the liver after allo-
geneic bone marrow transplantation, SMA expression
status in the setting of chemotherapy-induced sinus-
oidal endothelial injury in CRLM has only rarely been
described [17, 18]. Sato et al. described that the area
of activated HSCs significantly increased in zones 1
and 2, was more prominent in zone 3 of the hepatic
lobules after bone marrow transplantation compared
to normal liver tissues, and was much larger in zone 3
of liver tissues with VOD [31]. Rubbia-Brandt et al.
reported strong SMA reactivity in almost all HSCs
within the lobules, both along the dilated and intact
sinusoids in OX-induced SOS in patients with CRLM,
while sparse HSCs were SMA-positive in a small propor-
tion of control liver lobules [18]. In our study, SMA
expression in perisinusoidal HSCs was seen in 72.7% of
SOS+ cases, which was more frequent and extensive than
in the control group. These results are in agreement with
previous descriptions and indicate that HSC activation is a
salient feature of SOS.
Fig. 2 Common histologic features of SOS. a Shown are changes typical of sinusoidal obstruction (Case 12). Bridging bands of congestion were
observed connecting centrizonal areas (H&E, ×40). b In the same case, a trichrome stain highlights prominent fibrosis extending along centrilobular
sinusoids and also shows atrophic hepatocyte trabeculae (trichrome stain, ×200). c Nodular regenerative hyperplasia. In some cases (e.g., Case 6), the
hepatic parenchyma showed diffuse transformation into small nodules with little to no fibrosis (reticulin stain, ×40). d Venous occlusion. Case 14
showed complete fibrous obliteration of the central veins (H&E, ×100), which was further confirmed with Verhoeff–Van Gieson staining (inset, ×100)
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Recent experimental studies have suggested that normal
SECs of the liver function as a gatekeeper, preventing HSC
activation; however, once the SEC capillarizes, it no longer
prevents HSC activation and permits or promotes HSC ac-
tivation and subsequent fibrosis [30]. Because drugs and
toxins that cause SOS are selectively more toxic to SECs
than to hepatocytes, the disease is initiated by damage at
the sinusoid level. If present, prolonged loss of normal SEC
with capillarization permits HSC activation and perisinusoi-
dal fibrosis and fibrous occlusion of central venules in se-
vere cases. Thus, given the recent experimental evidence
that aberrant CD34 expression by SECs and subsequent
SMA overexpression by perisinusoidal HSCs are essential
in SOS initiation and development, immunohistochemical
labeling for CD34 and SMA appear to be a reasonable and
effective tool to identify CSI in patients with CRLM. The
frequent overexpression of these markers in cases with
histologically evident SOS in ours and a few other ob-
servational studies further support the feasibility of
these markers as diagnostic aids in this setting.
GS is exclusively expressed in a subpopulation of he-
patocytes situated adjacent to the central veins, and its
peculiar zonated distribution is considered to represent
a “fail-safe” mechanism for ammonia detoxification in
mammals [32]. Ammonia, arriving from the intestine via
the portal vein, is first metabolized by periportal hepato-
cytes through a low-affinity but high-capacity system in-
volving carbamoyl phosphate synthetase and arginase 1
to generate urea. If any ammonia escapes the periportal
hepatocytes, it can be scavenged and detoxified by perive-
nular hepatocytes through a high-affinity but low-capacity
system involving GS [33]. Recently, significant expansion
of the area of GS-expressing hepatocytes in human liver
has been demonstrated in certain circumstances such as
FNH, cirrhosis due to various causes, and idiopathic portal
hypertension [19–22]. Because these conditions are well
known to have altered microcirculation due to the pres-
ence of shunt vessels or abnormalities in venous and/or
arterial vessels, we tested the GS expression status based
on the assumption that an impaired sinusoidal microcir-
culation in CSI may lead to altered GS expression. In
SOS, there appears to be reduced plasma access to hepa-
tocytes due to SEC defenestration, basement membrane
formation, and perisinusoidal fibrosis. In severe cases,
sinusoidal perfusion might also be impaired due to micro-
thrombi and partial or total fibrous obliteration of the
central venules. Considering the fact that perivenular GS
plays an important physiological role as a downstream
Fig. 3 Aberrant expression of CD34, SMA, and GS in cases with sinusoidal obstruction syndrome were used to calculate the CSI score. a In case
12, the immunohistochemistry for CD34 showed confluent sinusoidal staining extending from the periportal to midzonal and centrizonal areas
(×100). This is an example of a immunohistochemistry grade 3 for CD34. b Immunohistochemical stain for SMA in the same case showed
confluent subsinusoidal staining in multiple areas (×200), which is also an example of a grade 3 staining intensity. c Immunohistochemistry
conducted on case 14 showed GS expression adjacent to an obliterated sublobular vein (arrow) that was expanded (×100) compared to the
normal perivenular GS staining pattern and was also give an immunohistochemistry score of 3. d In Case 19, aberrant confluent GS expression is
seen in midzonal and periportal areas; another example of a grade 3 pattern of staining (asterisks, central veins; arrow, portal tract; ×100)
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scavenger for ammonia, it is conceivable that aberrant
expression of GS in the midzonal and periportal hepatocytes
in SOS may possibly represent protective recruitment of he-
patocytes upstream from the perivenular area to maintain
overall hepatic ammonia disposal. In our study, aberrant GS
expression in the midzonal and periportal hepatocytes was
observed in 31.8% of SOS+ cases. Interestingly, most GS-
positive cases showed relatively high SOS-I, and none of the
control cases showed aberrant GS expression, but these
differences did not reach statistical significance. One limita-
tion of our study, was a low number of control cases that
had not received neoadjuvant chemotherapy prior to resec-
tion. This further supports how commonly these agents are
used, and with a larger population of patients GS staining
would have likely reached statistical significance.
The diagnosis of CSI should not be made based solely
on the histopathologic findings. The diagnosis of CSI/SOS
depends on a high index of clinical suspicion, after the clin-
ical exclusion of other potential mimicking causes of liver
injury. Several clinical features, such as hyperbilirubinemia,
hepatomegaly, ascites, weight gain, and splenomegaly, have
been associated with the development of SOS [34, 35],
although their sensitivity and specificity have not been well
defined. In the appropriate clinical setting, histological
examination of the background liver of the patients
with CRLM using SOS-I and the CSI scoring system
would certainly increase the diagnostic accuracy of CSI.
The major limitation of our study was that it compared
CRLM SOS+ cases that received chemotherapy with
control CRLM cases that did not. Future studies should
Fig. 4 CSI score. Comparison of CSI scores between the SOS+ and control groups (a). Comparison of CSI score between the cases with the
highest (SOS-I = 4) and lower SOS-I scores within the SOS+ group (b)
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use our panel to compare CRLM patients that received
chemotherapy and are SOS positive with those that
received chemotherapy and are SOS negative. This will
ensure that chemotherapy use alone does not result in
a positive staining pattern with our panel and an elevated
CSI score. These studies, combined with correlation of CIS
score to clinical features, will provide additional valuable in-
formation for the assessment of sensitivity and specificity of
CIS score for clinically significant chemotherapy-related
liver injury.
Conclusions
The CSI score, calculated using an immunohistochemical
panel consisting of CD34, SMA, and GS, may serve as an
objective marker of chemotherapy-induced sinusoidal in-
jury. The uniqueness of our study is although there are a
few others reports using these individual markers (SMA,
and CD34) as indicators of sinusoidal liver injury, ours is
the first to combine them and add GS into a scoring
system that can successfully diagnose CSI in liver biopsies
and resection specimens in patients with CRLM. Aberrant
CD34 expression by SECs and the increase in SMA-
positive HSCs seem to represent the pathologic conse-
quences of sinusoidal endothelial injury, and the altered
distribution pattern of GS-expressing hepatocytes may
represent an adaptive process reflecting impaired sinus-
oidal microcirculation. Notably, the abnormal staining
patterns for CD34, SMA, and GS were not necessarily
limited to the areas with sinusoidal dilatation/conges-
tion and appear less susceptible to sampling variability
in comparison with histologic evidence of sinusoidal
dilatation/congestion. Therefore, the simultaneous use
of these markers may increase the sensitivity for detect-
ing CSI.
Abbreviations
5-FU: 5-fluorouracil; CRLM: Colorectal liver metastases; CSI: Chemotherapy-
induced sinusoidal injury; FNH: Focal nodular hyperplasia; GS: Glutamine
synthetase; HSCs: Hepatic stellate cells; NRH: Nodular regenerative
hyperplasia; OX: Oxaliplatin; SECs: Sinusoidal endothelial cells; SMA: Smooth
muscle actin; SOS: Sinusoidal obstruction syndrome; SOS-I: Sinusoidal
obstruction syndrome index score; VOD: Veno-occlusive disease
Acknowledgements
We thank Dr. Yan Xie (Department of Pathology, University of Texas Medical
Branch) for statistical analysis support.
Funding
This work did not receive funding.
Availability of data and materials
The primary datasets supporting the conclusions of this article are included
within the article (Table 5).
Authors’ contributions
ES and HLS participated in the design of the study. MMP performed the
statistical analyses. All authors participated in discussion and contributed to
interpretation of data. All authors were involved in manuscript writing and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The ethics board of the University of Pittsburgh Medical Center recognized this
retrospective study was for quality-improvement purposes and did not require
ethics approval. This study was approved by Total Quality Council at the
Pittsburgh Medical Center, which waived the requirement for patients’ consent.
Author details
1Department of Pathology, The University of Texas Medical Branch, John
Sealy Annex Building - Room 2.148, 301 University Blvd., Galveston, TX
77555-0588, USA. 2Department of Pathology, The University of Texas Medical
Branch, John Sealy Annex Building, 301 University Blvd., Galveston, TX
77555-0588, USA. 3Department of Pathology and Laboratory Medicine, The
University of North Carolina at Chapel Hill Women’s & Children’s Hospitals,
Room 30212, 101 Manning Drive, Chapel Hill, NC 27514, USA.
Received: 11 May 2016 Accepted: 13 December 2016
References
1. Schlag PM, Benhidjeb T, Stroszczynski C. Resection and local therapy for
liver metastases. Best Pract Res Clin Gastroenterol. 2002;16:299–317.
2. Bartlett DL, Chu E. Can metastatic colorectal cancer be cured? Oncology
(Williston Park). 2012;26:266–75.
3. Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F,
Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert
D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH. Survival of patients
with initially unresectable colorectal liver metastases treated with FOLFOX/
cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM
study). Ann Oncol. 2014;25:1018–25.
4. McWhirter D, Kitteringham N, Jones RP, Malik H, Park K, Palmer D. Chemotherapy
induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms
and outcomes. Crit Rev Oncol Hematol. 2013;88:404–15.
5. Nguyen-Khac E, Lobry C, Chatelain D, Fuks D, Joly JP, Brevet M, Tramier B,
Mouly C, Hautefeuille V, Chauffert B, Regimbeau JM. A reappraisal of
chemotherapy-induced liver injury in colorectal liver metastases before the
era of antiangiogenics. Int J Hepatol. 2013;2013(314868):11.
6. Robinson SM, Wilson CH, Burt AD, Manas DM, White SA. Chemotherapy-
associated liver injury in patients with colorectal liver metastases: a
systematic review and meta-analysis. Ann Surg Oncol. 2012;19:4287–99.
7. Kneuertz PJ, Maithel SK, Staley CA, Kooby DA. Chemotherapy-associated
liver injury: impact on surgical management of colorectal cancer liver
metastases. Ann Surg Oncol. 2011;18:181–90.
8. Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive
disease). J Clin Exp Hepatol. 2014;4:332–46.
9. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, Brezault C,
Soubrane O, Abdalla EK, Vauthey JN, Mentha G, Terris B. Sinusoidal obstruction
syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-
associated liver lesions and partially prevented by bevacizumab in patients
with hepatic colorectal metastasis. Histopathology. 2010;56:430–9.
10. Morine Y, Shimada M, Utsunomiya T. Evaluation and management of
hepatic injury induced by oxaliplatin-based chemotherapy in patients with
hepatic resection for colorectal liver metastasis. Hepatol Res. 2014;44:59–69.
11. Vreuls CP, Van Den Broek MA, Winstanley A, Koek GH, Wisse E, Dejong CH,
Olde Damink SW, Bosman FT, Driessen A. Hepatic sinusoidal obstruction
syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver
metastases. Histopathology. 2012;61:314–8.
12. Viganò L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-
Brandt L. Liver resection for colorectal metastases after chemotherapy:
impact of chemotherapy-related liver injuries, pathological tumor response,
and micrometastases on long-term survival. Ann Surg. 2013;258:731–40.
13. Narita M, Oussoultzoglou E, Chenard MP, Rosso E, Casnedi S, Pessaux P,
Bachellier P, Jaeck D. Sinusoidal obstruction syndrome compromises liver
regeneration in patients undergoing two-stage hepatectomy with portal
vein embolization. Surg Today. 2011;41:7–17.
Stevenson et al. BMC Cancer  (2017) 17:35 Page 10 of 11
14. Narita M, Oussoultzoglou E, Chenard MP, Fuchshuber P, Rather M, Rosso E,
Addeo P, Jaeck D, Bachellier P. Liver injury due to chemotherapy-induced
sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
Ann Surg Oncol. 2012;19:2230–7.
15. Nalbantoglu IL, Tan Jr BR, Linehan DC, Gao F, Brunt EM. Histological features
and severity of oxaliplatin-induced liver injury and clinical associations. J Dig
Dis. 2014;15:553–60.
16. Blomhoff R, Wake K. Perisinusoidal stellate cells of the liver: important roles
in retinol metabolism and fibrosis. FASEB J. 1991;5:271–7.
17. Kang GH, Moon HS, Lee ES, Kim SH, Sung JK, Lee BS, Jeong HY, Lee HY,
Kang DY. A case of liver fibrosis with splenomegaly after oxaliplatin-based
adjuvant chemotherapy for colon cancer. J Korean Med Sci. 2013;28:1835–8.
18. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le
Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G,
Terris B. Severe hepatic sinusoidal obstruction associated with oxaliplatin-
based chemotherapy in patients with metastatic colorectal cancer. Ann
Oncol. 2004;15:460–6.
19. Bioulac-Sage P, Laumonier H, Rullier A, Cubel G, Laurent C, Zucman-Rossi J,
Balabaud C. Over-expression of glutamine synthetase in focal nodular
hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int.
2009;29:459–65.
20. Joseph NM, Ferrell LD, Jain D, Torbenson MS, Wu TT, Yeh MM, Kakar S.
Diagnostic utility and limitations of glutamine synthetase and serum
amyloid-associated protein immunohistochemistry in the distinction of focal
nodular hyperplasia and inflammatory hepatocellular adenoma. Mod Pathol.
2014;27:62–72.
21. Fleming KE, Wanless IR. Glutamine synthetase expression in activated hepatocyte
progenitor cells and loss of hepatocellular expression in congestion and cirrhosis.
Liver Int. 2013;33:525–34.
22. Sato Y, Harada K, Sasaki M, Nakanuma Y. Altered intrahepatic microcirculation
of idiopathic portal hypertension in relation to glutamine synthetase
expression. Hepatol Res. 2015;45:1323–30.
23. Song X, Zhao Z, Barber B, Gregory C, Wang PF, Long SR. Treatment patterns
and metastasectomy among mCRC patients receiving chemotherapy and
biologics. Curr Med Res Opin. 2011;27:123–30.
24. Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic therapy for
metastatic colorectal cancer: patterns of chemotherapy and biologic
therapy use in US medical oncology practice. J Oncol Pract. 2010;6:
301–7.
25. Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA.
Systemic cytotoxic and biological therapies of colorectal liver metastases:
expert consensus statement. HPB (Oxford). 2013;15:106–15.
26. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour
P, Bachellier P, Jaeck D. Sinusoidal injury increases morbidity after major
hepatectomy in patients with colorectal liver metastases receiving
preoperative chemotherapy. Ann Surg. 2008;247:118–24.
27. Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B,
Gruenberger T. Sinusoidal obstruction syndrome impairs long-term
outcome of colorectal liver metastases treated with resection after
neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18:421–30.
28. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids:
sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis.
2002;22:27–42.
29. Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression
of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in
normal human tissues. J Histochem Cytochem. 2006;54:385–95.
30. DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology.
2015;61:1740–6.
31. Sato Y, Asada Y, Hara S, Marutsuka K, Tamura K, Hayashi T, Sumiyoshi A.
Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver
after allogeneic bone marrow transplantation. Histopathology. 1999;34:
66–70.
32. Gebhardt R, Baldysiak-Figiel A, Krügel V, Ueberham E, Gaunitz F.
Hepatocellular expression of glutamine synthetase: an indicator of
morphogen actions as master regulators of zonation in adult liver. Prog
Histochem Cytochem. 2007;41:201–66.
33. Colnot S, Perret C. Liver zonation. In: Monga SPS, editor. Molecular pathology
of liver diseases. New York: Springer; 2011. p. 7–29.
34. Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, Veys P, Potter
MN, Haemato-oncology Task Force of British Committee for Standards in
Haematology; British Society for Blood and Marrow Transplantation. BCSH/
BSBMT guideline: diagnosis and management of veno-occlusive disease
(sinusoidal obstruction syndrome) following haematopoietic stem cell
transplantation. Br J Haematol. 2013;163:444–57.
35. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng
C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-mediated increase in
spleen size as a biomarker for the development of hepatic sinusoidal injury.
J Clin Oncol. 2010;28:2549–55.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Stevenson et al. BMC Cancer  (2017) 17:35 Page 11 of 11
